NEW YORK (GenomeWeb News) – Luminex reported after the close of the market a 10 percent rise in its third-quarter revenues, though the firm fell short of the consensus Wall Street estimate on the top line.

The Austin, Texas-based molecular diagnostics developer brought in total revenues of $50 million for the three months ended Sept. 30, up from $45.6 million for the third quarter of 2011. Analysts, on average, had expected revenues of $51.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.